{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:36:56Z","timestamp":1707525416960},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,15]]},"DOI":"10.7759\/cureus.48861","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T02:44:11Z","timestamp":1700102651000},"source":"Crossref","is-referenced-by-count":0,"title":["Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report"],"prefix":"10.7759","author":[{"given":"Gurdeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Michalek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy","volume":"11","author":"Bartalena L","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol (Lausanne). 2020, 11:615993. 10.3389\/fendo.2020.615993","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros P","year":"2017","unstructured":"Perros P, Heged\u00fcs L, Bartalena L, et al.. Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis. 2017, 12:72. 10.1186\/s13023-017-0625-1","journal-title":"Orphanet J Rare Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01459-7","article-title":"Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature","volume":"9","author":"Mu\u00f1oz-Ortiz J","year":"2020","unstructured":"Mu\u00f1oz-Ortiz J, Sierra-Cote MC, Zapata-Bravo E, et al.. Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature. Syst Rev. 2020, 9:201. 10.1186\/s13643-020-01459-7","journal-title":"Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10781","article-title":"A systematic review of euthyroid Graves' disease (Review)","volume":"22","author":"Macovei ML","year":"2021","unstructured":"Macovei ML, Azis \u0170, Gheorghe AG, Burcea M. A systematic review of euthyroid Graves' disease (Review). Exp Ther Med. 2021, 22:1346. 10.3892\/etm.2021.10781","journal-title":"Exp Ther Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves' disease: a meta-analysis and systematic review","volume":"93","author":"Chin YH","year":"2020","unstructured":"Chin YH, Ng CH, Lee MH, et al.. Prevalence of thyroid eye disease in Graves' disease: a meta-analysis and systematic review. Clin Endocrinol (Oxf). 2020, 93:363-74. 10.1111\/cen.14296","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01479-z","article-title":"Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression","volume":"44","author":"Ippolito S","year":"2021","unstructured":"Ippolito S, Cusini C, Lasalvia P, et al.. Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. J Endocrinol Invest. 2021, 44:1707-18. 10.1007\/s40618-020-01479-z","journal-title":"J Endocrinol Invest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4294","article-title":"Risk factors for Graves\u2019 orbitopathy; the Australian thyroid-associated orbitopathy Research (ATOR) study","volume":"101","author":"Khong JJ","year":"2016","unstructured":"Khong JJ, Finch S, De Silva C, Rylander S, Craig JE, Selva D, Ebeling PR. Risk factors for Graves\u2019 orbitopathy; the Australian thyroid-associated orbitopathy Research (ATOR) study. J Clin Endocrinol Metab. 2016, 101:2711-20. 10.1210\/jc.2015-4294","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2813","article-title":"Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease","volume":"91","author":"Eckstein AK","year":"2006","unstructured":"Eckstein AK, Plicht M, Lax H, et al.. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006, 91:3464-70. 10.1210\/jc.2005-2813","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0430","article-title":"High serum cholesterol is a novel risk factor for Graves\u2019 orbitopathy: results of a cross-sectional study","volume":"28","author":"Sabini E","year":"2018","unstructured":"Sabini E, Mazzi B, Profilo MA, et al.. High serum cholesterol is a novel risk factor for Graves\u2019 orbitopathy: results of a cross-sectional study. Thyroid. 2018, 28:386-94. 10.1089\/thy.2017.0430","journal-title":"Thyroid"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(14)72787-4","article-title":"Diagnostic criteria for Graves' ophthalmopathy","volume":"119","author":"Bartley GB","year":"1995","unstructured":"Bartley GB, Gorman CA. Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol. 1995, 119:792-5. 10.1016\/s0002-9394(14)72787-4","journal-title":"Am J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/01.iop.0000235499.34867.85","article-title":"VISA classification for Graves orbitopathy","volume":"22","author":"Dolman PJ","year":"2006","unstructured":"Dolman PJ, Rootman J. VISA classification for Graves orbitopathy. Ophthalmic Plast Reconstr Surg. 2006, 22:319-24. 10.1097\/01.iop.0000235499.34867.85","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena L","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, et al.. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021, 185:G43-67. 10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/249125","article-title":"Graves\u2019 ophthalmopathy: Visa versus EUGOGO classification, assessment, and management","volume":"2015","author":"Barrio-Barrio J","year":"2015","unstructured":"Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Vel\u00e1zquez-Villoria \u00c1, Galofr\u00e9 JC. Graves\u2019 ophthalmopathy: Visa versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015, 2015:249125. 10.1155\/2015\/249125","journal-title":"J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease\u00a0: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch HB","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, et al.. Management of thyroid eye disease\u00a0: a consensus statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J. 2022, 11:10.1530\/ETJ-22-0189","journal-title":"Eur Thyroid J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes","volume":"99","author":"Chen H","year":"2014","unstructured":"Chen H, Mester T, Raychaudhuri N, Kauh CY, Gupta S, Smith TJ, Douglas RS. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014, 99:E1635-40. 10.1210\/jc.2014-1580","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas RS","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, et al.. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020, 382:341-52. 10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith TJ","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, et al.. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017, 376:1748-61. 10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000894","article-title":"Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment","volume":"34","author":"Johnson BT","year":"2021","unstructured":"Johnson BT, Jameyfield E, Aakalu VK. Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment. Curr Opin Neurol. 2021, 34:116-21. 10.1097\/WCO.0000000000000894","journal-title":"Curr Opin Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s5228","article-title":"Update on thyroid eye disease and management","volume":"3","author":"Bothun ED","year":"2009","unstructured":"Bothun ED, Scheurer RA, Harrison AR, Lee MS. Update on thyroid eye disease and management. Clin Ophthalmol. 2009, 3:543-51. 10.2147\/opth.s5228","journal-title":"Clin Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3283499446","article-title":"The pathophysiology of thyroid eye disease: implications for immunotherapy","volume":"22","author":"Douglas RS","year":"2011","unstructured":"Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol. 2011, 22:385-90. 10.1097\/ICU.0b013e3283499446","journal-title":"Curr Opin Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.07.021","article-title":"A new era in the treatment of thyroid eye disease","volume":"208","author":"Patel A","year":"2019","unstructured":"Patel A, Yang H, Douglas RS. A new era in the treatment of thyroid eye disease. Am J Ophthalmol. 2019, 208:281-8. 10.1016\/j.ajo.2019.07.021","journal-title":"Am J Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity","volume":"96","author":"Zang S","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011, 96:320-32. 10.1210\/jc.2010-1962","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1995.tb01214","article-title":"Euthyroid Graves' disease showing no thyroid abnormalities except positive thyroid-stimulating antibody (TSAb): two case reports","volume":"238","author":"Watanabe M","year":"1995","unstructured":"Watanabe M, Iwatani Y, Kashiwai T, Iijima T, Fujikado T, Amino N. Euthyroid Graves' disease showing no thyroid abnormalities except positive thyroid-stimulating antibody (TSAb): two case reports. J Intern Med. 1995, 238:379-84. 10.1111\/j.1365-2796.1995.tb01214","journal-title":"J Intern Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena L","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W, et al.. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab. 2012, 97:4454-63. 10.1210\/jc.2012-2389","journal-title":"J Clin Endocrinol Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_3217_21","article-title":"Update on thyroid eye disease: regional variations in prevalence, diagnosis, and management","volume":"70","author":"Yu CY","year":"2022","unstructured":"Yu CY, Ford RL, Wester ST, Shriver EM. Update on thyroid eye disease: regional variations in prevalence, diagnosis, and management. Indian J Ophthalmol. 2022, 70:2335-45. 10.4103\/ijo.IJO_3217_21","journal-title":"Indian J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves' orbitopathy","volume":"364","author":"Marcocci C","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, et al.. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011, 364:1920-31. 10.1056\/NEJMoa1012985","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030809","article-title":"A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy","volume":"89","author":"Prummel MF","year":"2004","unstructured":"Prummel MF, Terwee CB, Gerding MN, et al.. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab. 2004, 89:15-20. 10.1210\/jc.2003-030809","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(01)00632-7","article-title":"A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy","volume":"108","author":"Gorman CA","year":"2001","unstructured":"Gorman CA, Garrity JA, Fatourechi V, et al.. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001, 108:1523-34. 10.1016\/s0161-6420(01)00632-7","journal-title":"Ophthalmology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi M","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, et al.. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015, 100:422-31. 10.1210\/jc.2014-3014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan MN","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab. 2015, 100:432-41. 10.1210\/jc.2014-2572","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0269","article-title":"Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy","volume":"31","author":"Vannucchi G","year":"2021","unstructured":"Vannucchi G, Campi I, Covelli D, et al.. Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid. 2021, 31:821-8. 10.1089\/thy.2020.0269","journal-title":"Thyroid"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2017.07.001","article-title":"Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy","volume":"7","author":"Russell DJ","year":"2017","unstructured":"Russell DJ, Wagner LH, Seiff SR. Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy. Am J Ophthalmol Case Rep. 2017, 7:146-8. 10.1016\/j.ajoc.2017.07.001","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves' orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras JV","year":"2014","unstructured":"P\u00e9rez-Moreiras JV, Alvarez-L\u00f3pez A, G\u00f3mez EC. Treatment of active corticosteroid-resistant graves' orbitopathy. Ophthalmic Plast Reconstr Surg. 2014, 30:162-7. 10.1097\/IOP.0000000000000037","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras JV","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al.. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018, 195:181-90. 10.1016\/j.ajo.2018.07.038","journal-title":"Am J Ophthalmol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0716","article-title":"Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor","volume":"89","author":"Smith TJ","year":"2004","unstructured":"Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004, 89:5076-80. 10.1210\/jc.2004-0716","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2890","article-title":"A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody","volume":"97","author":"Kumar S","year":"2012","unstructured":"Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. J Clin Endocrinol Metab. 2012, 97:1681-7. 10.1210\/jc.2011-2890","journal-title":"J Clin Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith TJ","year":"2019","unstructured":"Smith TJ, Janssen JA. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2019, 40:236-67. 10.1210\/er.2018-00066","journal-title":"Endocr Rev"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S303057","article-title":"Efficacy and safety of teprotumumab in thyroid eye disease","volume":"17","author":"Teo HM","year":"2021","unstructured":"Teo HM, Smith TJ, Joseph SS. Efficacy and safety of teprotumumab in thyroid eye disease. Ther Clin Risk Manag. 2021, 17:1219-30. 10.2147\/TCRM.S303057","journal-title":"Ther Clin Risk Manag"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac168","article-title":"Teprotumumab and the evolving therapeutic landscape in thyroid eye disease","volume":"107","author":"Kossler AL","year":"2022","unstructured":"Kossler AL, Douglas R, Dosiou C. Teprotumumab and the evolving therapeutic landscape in thyroid eye disease. J Clin Endocrinol Metab. 2022, 107:S36-46. 10.1210\/clinem\/dgac168","journal-title":"J Clin Endocrinol Metab"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas RS","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, et al.. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022, 129:438-49. 10.1016\/j.ophtha.2021.10.017","journal-title":"Ophthalmology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/181010-refractory-thyroid-eye-disease-unresponsive-to-teprotumumab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:26Z","timestamp":1707509186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/181010-refractory-thyroid-eye-disease-unresponsive-to-teprotumumab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.48861","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,15]]}}}